The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 1×
“In the brain, cannabinoids activate the type 1 cannabinoid (CB1) receptor, which is densely expressed in a number of regions related to the modulation of fear and anxiety (Mackie, 2005; Pacher et al., 2006).”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 4×
“Indeed, increased levels of eCBs were observed during aversive stimuli in key regions related to fear and anxiety responses, where this system may act on-demand to oppose the impact of stress (Marsicano et al., 2002).”
BackgroundInfluentialSelf-citationBourin, M., & Hascoët, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01274-3 · Cited by 1,427
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on
Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 1,005
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Self-citationHall, W., & Solowij, N. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05021-1 · Cited by 772
Distribution of cannabinoid receptors in the central and peripheral nervous system
Mackie, K. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_10 · Cited by 744 · cited 1×
“In the brain, cannabinoids activate the type 1 cannabinoid (CB1) receptor, which is densely expressed in a number of regions related to the modulation of fear and anxiety (Mackie, 2005; Pacher et al., 2006).”
BackgroundThe Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus
Monory, K., Massa, F., Egertová, M., Eder, M., Blaudzun, H., Westenbroek, R., Kelsch, W., Jacob, W., Marsch, R., Ekker, M., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.006 · Cited by 706
Self-citationStructure and function of fatty acid amide hydrolase
McKinney, M. K., & Cravatt, B. F. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133450 · Cited by 680 · cited 1×
“Their actions are terminated by a putative uptake process, followed by degradation by fatty acid amide hydrolase (FAAH) and by monoacylglycerol lipase (McKinney and Cravatt, 2005), respectively.”
BackgroundGobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509591102 · Cited by 673
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Anandamide and vanilloid TRPV1 receptors
Ross, R. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705467 · Cited by 604
Jiang, W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25509 · Cited by 527
Involvement of CB1 cannabinoid receptors in emotional behaviour
Martin, M., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 507
Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., & Di Marzo, V. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.074 · Cited by 491
Endocannabinoid system and stress and anxiety responses
VIVEROS, M., MARCO, E., & FILE, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.029 · Cited by 485
Pain modulation by release of the endogenous cannabinoid anandamide
Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K., & Sañudo-Peña, M. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12198 · Cited by 485
Patel, S., & Hillard, C. J. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101287 · Cited by 392
A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals
Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606646200 · Cited by 363
Experimental Approaches to Anxiety and Depression
Elliott, J. M., Heal, D. J., & Mardens, C. A. (1993) · Behavioural Pharmacology · doi:10.1097/00008877-199310000-00012 · Cited by 361
Marsch, R., Foeller, E., Rammes, G., Bunck, M., Kössl, M., Holsboer, F., Zieglgänsberger, W., Landgraf, R., Lutz, B., & Wotjak, C. T. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3303-06.2007 · Cited by 359
Self-citationPharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 311
Navarro, M., Hernández, E., Muñoz, R. M., del Arco, I., Villanúa, M. A., Carrera, M. R. A., & Rodríguez de Fonseca, F. (1997) · NeuroReport · doi:10.1097/00001756-199701200-00023 · Cited by 306
A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze
Mechiel Korte, S., & De Boer, S. F. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01279-2 · Cited by 297
Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03293.x · Cited by 284
A hitchhiker's guide to behavioral analysis in laboratory rodents
Sousa, N., Almeida, O. F. X., & Wotjak, C. T. (2006) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2006.00228.x · Cited by 276
Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404
Bortolato, M., Campolongo, P., Mangieri, R. A., Scattoni, M. L., Frau, R., Trezza, V., La Rana, G., Russo, R., Calignano, A., Gessa, G. L., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301061 · Cited by 231
Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol
Berrendero, F., & Maldonado, R. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1144-9 · Cited by 222
Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes
Kamprath, K., Marsicano, G., Tang, J., Monory, K., Bisogno, T., Marzo, V. D., Lutz, B., & Wotjak, C. T. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0153-06.2006 · Cited by 217
Self-citationA FAAH-Regulated Class of N-Acyl Taurines That Activates TRP Ion Channels
Saghatelian, A., McKinney, M. K., Bandell, M., Patapoutian, A., & Cravatt, B. F. (2006) · Biochemistry · doi:10.1021/bi0608008 · Cited by 212
Experimental approaches to anxiety and depression
McCall, W. V. (1993) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(93)90335-v · Cited by 186
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184 · cited 7×
“such as the intensity of illumination, may influence the effects of CB1 activation or blockade (Haller et al., 2004a; Naidu et al., 2007).”
BackgroundMethodResultInfluentialVarvel, S. A., Wise, L. E., Niyuhire, F., Cravatt, B. F., & Lichtman, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301224 · Cited by 173
Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray
Moreira, F. A., de Aguiar, D. C., & Guimarães, F. S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.013 · Cited by 160
Self-citationMarco, E. M., rez-Alvarez, L. P., Borcel, É., Rubio, M., Guaza, C., Ambrosio, E., File, S. E., & Viveros, M. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200402000-00003 · Cited by 133
Hill, M. N., Kambo, J. S., Sun, J. C., Gorzalka, B. B., & Galea, L. A. M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05061.x · Cited by 106
Rodgers, R. J., Evans, P., & Murphy, A. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00013 · Cited by 102
Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors
Kasckow, J., Mulchahey, J. J., & Geracioti, T. D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.007 · Cited by 91
Lapin, I. P. (1995) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/1056-8719(95)00025-d · Cited by 83
Effects of cannabinoids on the anxiety-like response in mice.
Rutkowska, M., Jamontt, J., & Gliniak, H. (2006) · PubMed · Cited by 66
Wise, L. E., Shelton, C. C., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.002 · Cited by 41
Cited by
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
The endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506
Self-citationNew approaches and challenges to targeting the endocannabinoid system
Di Marzo, V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480
Metadata
- Authors
- Moreira, F. A., Kaiser, N., Monory, K., & Lutz, B.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 54
- Issue
- 1
- Pages
- 141-150
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2018723047
- Cited by
- 281
- References
- 45
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.